UNSPSC 51401555: Tofisopam

This classification denotes an anxiolytic with the molecular formula C22H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZC80HAU42, chemically known as 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5h-2,3-benzodiazepine but generally known as tofisopam, which bears US NIH Compound Identifier 5502. European Medicines Agency schedules Tofisopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11144MIG.

UNSPSC 51401555 Tofisopam is a Commodity code that reflects state and local procurement of pharmaceutical products, though recent solicitations under this code show purchases of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and OTC products rather than tofisopam specifically. State and local governments procuring under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Issuing bodies include county public health operations, state pharmacy benefit programs, and multistate cooperative purchasing vehicles that aggregate demand across participating state and local members. The work involves establishing supply contracts for pharmaceutical products, including emergency response medications, generic pharmaceuticals, and over-the-counter items, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance and operational requirements.

Recent activity shows three representative opportunities: Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas Health and Human Services Commission released RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers across participating state and local facilities including Oregon, with awards effective July 1, 2026. Geographic activity centers on Florida, Texas, and the upper Midwest, with cooperative purchasing mechanisms extending reach across multiple states. Vendors must navigate electronic procurement portals, provide detailed product and pricing documentation, maintain authorized wholesaler relationships, and comply with federal environmental and drug-supply regulations, with contracts typically spanning two years with renewal options.